TwinHealth, a startup using AI and wearables to manage chronic metabolic conditions, has launched a digital twin program to treat obesity.
Merck and Kelun-Biotech reveal positive phase 3 breast cancer data from their antibody-drug conjugate.
A HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of a broadly neutralizing HIV antibody in a small group of people in clinical trial.
AstraZeneca lost lawsuit against Pfizer and now has to pay them $107.5 million for infringing on their patient for cancer drug Tagrisso.
AstraZeneca has the option of buying startup SixPeaks Bio, operating in the obesity field.
The combination of Merck KGaA's Bavencio and Pfizer's Inlyta fails the overall survival endpoint in a stage 3 trial for newly diagnosed advanced kidney cancer.
NovoNordisk's semaglutide cut the risk of major cardiovascular events and death in phase 3 trial with patients with diabetes and chronic kidney disease.
Boehringer Ingelheim reveals their 10-year plan and their intention to overtake Bayer as Germany's largest pharma company.
AstraZeneca makes a $19 million deal with Nona Biosciences with the intention to create antibody-based targeted cancer treatments.
Merck returns to the eye disease market with a $3 billion cash acquisition of EyeBio.
56%of HCPs in one study indicated that they would be interested in AI diagnostic aid tools to relieve some burden from their plates.
Eli Lilly invests a further $5.3 billion into the production of obesity and diabetes drugs.
Digital health company Hims & Hers plans to offer custom versions of popular weightloss shots.
The FDA is working to improve their clinical trial process through patient listening sessions, publishing guidance for inclusive enrollment, leveraging digital health tech to make them more accessible, and launching The Center for Clinical Trials Innovation.
Louisiana governor signs new law that limits the ability of HCPs to prescribe abortion medications.
%402x.svg){kind=icon}
.png)
%402x.svg){kind=icon}
